Fierce Biotech

• French vaccine maker Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles.

• As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.

• Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines.

• The FDA has delayed a decision on Ascendis Pharma’s dwarfism drug candidate TransCon CNP, pushing back the deadline by three months to buy time to review recently submitted information.

• A federal commission is warning that the U.S. is losing its innovative edge, arguing that the nation needs to “reimagine the federal science enterprise” by streamlining funding and incorporating AI into processes.